Hamilton Thorne Ltd.
Presenter: Meg Spencer, CEO
Company Information
Company Type: Medical Technologies
Development Stage: Public
Company Profile
Hamilton Thorne (TSX-V: HTL)
Hamilton Thornes advanced laser systems and instruments are rapidly emerging as the dominant products to facilitate precise procedures in the stem cell research and fertility clinic markets. Hamilton Thornes lead products, the ZILOS-tk and XYClone laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, embryo, reproductive toxicology and living cell procedures.
Hamilton Thornes growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.
Meg Spencer, Chief Executive Officer and Co-Founder
Ms. Spencer brought 17 years experience in the field of regenerative medicine and other technology markets to Hamilton Thorne when she founded the present company in 2001. She founded two previous companies, taking each from start-up to global market leadership in their respective sectors. Hamilton Equine Systems, Inc., a high tech veterinary products company, was successfully sold at an attractive ROI for its investors. Hamilton-Thorne Research offered reproductive toxicology testing systems for the study of the effects of chemicals, pesticides and prescription drugs on human and animal reproduction.
Spencer has identified important problems in Stem Cell, transgenic research and molecular diagnostics; she has raised capital, sought and licensed key enabling technologies, forged accelerated university product development programs (with the Public Health Research Institute, Mount Sinai School of Medicine, and Boston University), established international distribution channels and strategic sales alliances, and pushed through development of proprietary in-house technologies to revolutionize stem cell and transgenic research. Establishment of a top management team was accomplished successfully.
Education: Harvard University and George Washington University.
Presenter Bio
Meg Spencer, Chief Executive Officer and Co-Founder
Ms. Spencer brought 17 years experience in the field of regenerative medicine and other technology markets to Hamilton Thorne when she founded the present company in 2001. She founded two previous companies, taking each from start-up to global market leadership in their respective sectors. Hamilton Equine Systems, Inc., a high tech veterinary products company, was successfully sold at an attractive ROI for its investors. Hamilton-Thorne Research offered reproductive toxicology testing systems for the study of the effects of chemicals, pesticides and prescription drugs on human and animal reproduction.
Spencer has identified important problems in Stem Cell, transgenic research and molecular diagnostics; she has raised capital, sought and licensed key enabling technologies, forged accelerated university product development programs (with the Public Health Research Institute, Mount Sinai School of Medicine, and Boston University), established international distribution channels and strategic sales alliances, and pushed through development of proprietary in-house technologies to revolutionize stem cell and transgenic research. Establishment of a top management team was accomplished successfully.
Education: Harvard University and George Washington University.
Contact
Hamilton Thorne Ltd.
100 Cummings Center, 465E
Beverly
MA, USA
01915
ph: 978 921 2050
fx: 978 921 0250
www.hamiltonthorne.com
mms@hamiltonthorne.com